Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘iTeos’

Time for some additional colour commentary!

There has been some incredibly intense interest surrounding TIGIT as a new therapeutic target in oncology of late, to the point where some observers have been wildly claiming this is the new universal checkpoint everyone has been waiting for.

But is it?

It’s early days yet with little data presented from people with cancer, so at this point it could well be a bit of a stretch to find another anti-PD–1/PD-L1 equivalent, but this doesn’t mean there isn’t utility in seeing clinical activity in some tumour types, far from it.

In our latest post, we take a look at what’s coming up in the TIGIT niche, along with an interview from a company active in this niche.

What do the company have to say and how do they see this panning out?

To learn more from our oncology analysis and get a heads up on insights and commentary on a new checkpoint target called TIGIT subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Making waves with new directions – there are many possible ways to go when considering targeting the adenosine axis

As we segue between our AACR and ASCO coverage, one topic that straddles both virtual meetings is targeting the adenosine axis.  At AACR19, this pathway was very much front and square with some intriguing and controversial data presented, which caught many people by surprise.

Since then, several companies have opened new trials, others are completing enrollment and waiting for their data to readout before deciding upon next steps.

It’s a good time to take a look at what’s new in this niche and also see things differently through the lens of one company involved in the field.  Yes, it’s time to share our latest expert interview from not one, but two, c-suite executives.

What are their perspectives (they are different), where do they see the field going and why?

In part one of the discussion we focus exclusively on adenosine targeting and how they see themselves differentiated from the crowd… it certainly makes for interesting reading!

To learn more from our oncology analysis and get a heads up on insights and commentary on the adenosine axis subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

For the last couple of years at every annual meeting of the American Society of Hematology (ASH) conference, I have posted an extensive Preview of the CAR T cell therapy landscape and looked at which abstracts piqued my interest.

The roaring 30s CAR

This year the review is the most extensive to date, with more companies, more research groups, more tumour types and way more preclinical research coming through. It’s like a kaleidoscope of ideas cascading through R&D.

The other thing to take note is how fast the field is moving – it’s warp speed now and so much comes through the literature every month on top of that.

So here we go – hold onto your hats as there is a LOT to contemplate this year!

To get a heads up and learn more insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!